Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy

The hallmarks of cancer

Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219

Current Protocols in Immunology

(2018) · Current Protocols in Immunology · doi:10.1002/(issn)1934-368x · Cited by 3,574

Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism

Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I. E., Conway, S. J., Marshall, B., Brown, C. C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,589

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305

Cytokines in cancer pathogenesis and cancer therapy

Dranoff, G. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1252 · Cited by 1,660

Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism

Munn, D. H., Shafizadeh, E., Attwood, J. T., Bondarev, I. E., Pashine, A., & Mellor, A. L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1363 · Cited by 1,640

BAR Domains as Sensors of Membrane Curvature: The Amphiphysin BAR Structure

Peter, B. J., Kent, H. M., Mills, I. G., Vallis, Y., Butler, P. J. G., Evans, P. R., & McMahon, H. T. (2004) · Science · doi:10.1126/science.1092586 · Cited by 1,636

Current protocols in immunology

Nezlin, R. S. (1992) · Molecular Immunology · doi:10.1016/0161-5890(92)90114-d · Cited by 1,413

Colorectal carcinoma antigens detected by hybridoma antibodies

Koprowski, H., Steplewski, Z., Mitchell, K. F., Herlyn, M., Herlyn, D., & Fuhrer, P. (1979) · Somatic Cell and Molecular Genetics · doi:10.1007/bf01542654 · Cited by 1,360

Escape of Human Solid Tumors from T–Cell Recognition: Molecular Mechanisms and Functional Significance

Marincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,185

Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury

Degterev, A., Huang, Z., Boyce, M., Li, Y., Jagtap, P., Mizushima, N., Cuny, G. D., Mitchison, T. J., Moskowitz, M. A., & Yuan, J. (2005) · Nature Chemical Biology · doi:10.1038/nchembio711 · Cited by 3,068

Understanding the Intersections between Metabolism and Cancer Biology

Heiden, M. G. V., & DeBerardinis, R. J. (2017) · Cell · doi:10.1016/j.cell.2016.12.039 · Cited by 2,369

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

Opitz, C. A., Litzenburger, U. M., Sahm, F., Ott, M., Tritschler, I., Trump, S., Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., et al. (2011) · Nature · doi:10.1038/nature10491 · Cited by 1,898

Immunosuppressive Strategies that are Mediated by Tumor Cells

Rabinovich, G. A., Gabrilovich, D. I., & Sotomayor, E. M. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,747

Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond

Platten, M., Nollen, E. A. A., Röhrig, U. F., Fallarino, F., & Opitz, C. A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0016-5 · Cited by 1,586

Genetics and biology of pancreatic ductal adenocarcinomaPreprint

Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N. M., & DePinho, R. A. (2006) · Genes & Development · doi:10.1101/gad.1415606 · Cited by 1,611

Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy

Sica, A., Schioppa, T., Mantovani, A., & Allavena, P. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.003 · Cited by 1,483

Impact of the Gut Microbiota on Intestinal Immunity Mediated by Tryptophan Metabolism

Gao, J., Xu, K., Liu, H., Liu, G., Bai, M., Peng, C., Li, T., & Yin, Y. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00013 · Cited by 1,357

Indoleamine 2,3-dioxygenase and tumor-induced tolerance

Munn, D. H., & Mellor, A. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31178 · Cited by 1,093

The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages.

Allavena, P., Sica, A., Solinas, G., Porta, C., & Mantovani, A. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.07.004 · Cited by 1,044

Indoleamine 2,3 dioxygenase and metabolic control of immune responses

Munn, D. H., & Mellor, A. L. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.10.001 · Cited by 1,037

IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance

Munn, D. H., & Mellor, A. L. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.002 · Cited by 1,081

The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor ζ-Chain and Induce a Regulatory Phenotype in Naive T Cells

Fallarino, F., Grohmann, U., You, S., McGrath, B. C., Cavener, D. R., Vacca, C., Orabona, C., Bianchi, R., Belladonna, M. L., Volpi, C., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.11.6752 · Cited by 1,078

Tryptophan metabolism in health and disease

Chen, X., Li, G., Zheng, Q., Gu, X., Shi, Q., Su, Y., Chu, Q., Yuan, X., Bao, Z., Lu, J., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.06.004 · Cited by 1,035

Regulation of the immune response by the aryl hydrocarbon receptor

Gutiérrez-Vázquez, C., & Quintana, F. J. (2018) · Immunity · doi:10.1016/j.immuni.2017.12.012 · Cited by 985

The Sorcerer II Global Ocean Sampling Expedition: Expanding the Universe of Protein Families

Yooseph, S., Sutton, G., Rusch, D. B., Halpern, A. L., Williamson, S. J., Remington, K., Eisen, J. A., Heidelberg, K. B., Manning, G., Li, W., et al. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050016 · Cited by 925

Role of tumor-associated macrophages in tumor progression and invasion

Mantovani, A., Schioppa, T., Porta, C., Allavena, P., & Sica, A. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9001-7 · Cited by 901

Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence

Rajman, L., Chwalek, K., & Sinclair, D. A. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.011 · Cited by 865

Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase

Sharma, M. D., Baban, B., Chandler, P., Hou, D., Singh, N., Yagita∥, H., Azuma, M., Blazar, B. R., Mellor, A. L., & Munn, D. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31911 · Cited by 791

Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion

Platten, M., Wick, W., & den Eynde, B. J. V. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0569 · Cited by 725

Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells

Pallotta, M. T., Orabona, C., Volpi, C., Vacca, C., Belladonna, M. L., Bianchi, R., Servillo, G., Brunacci, C., Calvitti, M., Bicciato, S., et al. (2011) · Nature Immunology · doi:10.1038/ni.2077 · Cited by 737

The Yin‐Yang of tumor‐associated macrophages in neoplastic progression and immune surveillance

Allavena, P., Sica, A., Garlanda, C., & Mantovani, A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00607.x · Cited by 647

Kynurenines in the CNS: recent advances and new questions

Vécsei, L., Szalárdy, L., Fülöp, F., & Toldi, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3793 · Cited by 641

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

Holmgaard, R., Zamarin, D., Munn, D. H., Wolchok, J. D., & Allison, J. P. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20130066 · Cited by 646

Kynurenine Pathway Metabolites in Humans: Disease and Healthy States

Chen, Y., & Guillemin, G. J. (2009) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s2097 · Cited by 642

Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells

Brandacher, G., Perathoner, A., Ladurner, R., Schneeberger, S., Obrist, P., Winkler, C., Werner, E. R., Werner-Felmayer, G., Weiss, H. G., G√∂bel, G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1966 · Cited by 614

Emerging blood–brain-barrier-crossing nanotechnology for brain cancer theranostics

Tang, W., Fan, W., Lau, J., Deng, L., Shen, Z., & Chen, X. S. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00805a · Cited by 610

Cancer related inflammation: the macrophage connection

Sica, A., Allavena, P., & Mantovani, A. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.028 · Cited by 601

Inhibition of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Stereoisomers of 1-Methyl-Tryptophan Correlates with Antitumor Responses

Hou, D., Muller, A. J., Sharma, M. D., DuHadaway, J. B., Banerjee, T., Johnson, M., Mellor, A. L., Prendergast, G. C., & Munn, D. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2925 · Cited by 592

Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase

Pilotte, L., Larrieu, P., Stroobant, V., Colau, D., Dolušić, E., Frédérick, R., Plaen, E. D., Uyttenhove, C., Wouters, J., Masereel, B., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113873109 · Cited by 582

Mitochondrial complex I inhibition triggers a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis in melanoma cells

Basit, F., van Oppen, L. M. P. E., Schöckel, L., Bossenbroek, H. M., Vries, S. E. V. E., Hermeling, J. C., Grefte, S., Kopitz, C., Héroult, M., Willems, P. H. G. M., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.133 · Cited by 574

Pancreatic cancer: from state-of-the-art treatments to promising novel therapies

Garrido‐Laguna, I., & Hidalgo, M. M. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.53 · Cited by 576

Discovery of IDO1 Inhibitors: From Bench to Bedside

Prendergast, G. C., Malachowski, W. P., DuHadaway, J. B., & Muller, A. J. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2285 · Cited by 571

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

Liu, X., Shin, N., Koblish, H. K., Yang, G., Wang, Q., Wang, K., Leffet, L., Hansbury, M., Thomas, B. A., Rupar, M. J., et al. (2010) · Blood · doi:10.1182/blood-2009-09-246124 · Cited by 559

Genetics and biology of pancreatic ductal adenocarcinoma

Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016) · Genes & Development · doi:10.1101/gad.275776.115 · Cited by 527

Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer

Prendergast, G. C., Smith, C., Thomas, S., Mandik‐Nayak, L., Laury‐Kleintop, L. D., Metz, R. A., & Muller, A. J. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1549-4 · Cited by 491

Classification of current anticancer immunotherapies

Galluzzi, L., Vacchelli, E., Pedro, J. M. B., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 481

Novel Tryptophan Catabolic Enzyme IDO2 Is the Preferred Biochemical Target of the Antitumor Indoleamine 2,3-Dioxygenase Inhibitory Compound d -1-Methyl-Tryptophan

Metz, R. A., DuHadaway, J. B., Kamasani, U. R., Laury‐Kleintop, L. D., Muller, A. J., & Prendergast, G. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1872 · Cited by 482

Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models

Takahashi, N., Duprez, L., Grootjans, S., Cauwels, A., Nerinckx, W., DuHadaway, J. B., Goossens, V, Roelandt, R., Van Hauwermeiren, F., Libert, C., et al. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.176 · Cited by 465

Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets

Shi, Y., Du, L., Lin, L., & Wang, Y. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.193 · Cited by 463

IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-κB activation

Puccetti, P., & Grohmann, U. (2007) · Nature reviews. Immunology · doi:10.1038/nri2163 · Cited by 469

Targeting the IDO1 pathway in cancer: from bench to bedside

Liu, M., Wang, X., Wang, L., Ma, X., Gong, Z., Zhang, S., & Li, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0644-y · Cited by 456

Biologically active quinoline and quinazoline alkaloids part I

Shang, X., Morris-Natschke, S. L., Liu, Y., Guo, X., Xu, X., Goto, M., Li, J., Yang, G., & Lee, K. (2017) · Medicinal Research Reviews · doi:10.1002/med.21466 · Cited by 446

Regulation of HIF-1α Stability through S-Nitrosylation

Li, F., Sonveaux, P., Rabbani, Z. N., Liu, S., Yan, B., Huang, Q., Vujašković, Ž., Dewhirst, M. W., & Li, C. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.02.024 · Cited by 447

Plasma Free Amino Acid Profiling of Five Types of Cancer Patients and Its Application for Early Detection

Miyagi, Y., Higashiyama, M., Gochi, A., Akaike, M., Ishikawa, T., Miura, T., Saruki, N., Bando, E., Kimura, H., Imamura, F., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024143 · Cited by 439

Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?

Löb, S., Königsrainer, A., Rammensee, H., Opelz, G., & Terness, P. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2639 · Cited by 421

Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis

Labadie, B. W., Bao, R., & Luke, J. J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2882 · Cited by 413

Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy

Colombo, M. P., & Piconese, S. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2250 · Cited by 414

Indoleamine 2,3‐dioxygenase in T‐cell tolerance and tumoral immune escape

Katz, J. B., Muller, A. J., & Prendergast, G. C. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00610.x · Cited by 417

Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases

Lovelace, M. D., Varney, B., Sundaram, G., Lennon, M. J., Lim, C. K., Jacobs, K., Guillemin, G. J., & Brew, B. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.024 · Cited by 393

Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives

Godin-Ethier, J., Hanafi, L., Piccirillo, C. A., & Lapointe, R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1331 · Cited by 398

Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells

Okamoto, A., Nikaido, T., Ochiai, K., Takakura, S., Saito, M., Aoki, Y., Ishii, N., Yanaihara, N., Yamada, K., Takikawa, O., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2671 · Cited by 399

IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan

Metz, R. A., Rust, S., DuHadaway, J. B., Mautino, M. R., Munn, D. H., Vahanian, N. N., Link, C. J., & Prendergast, G. C. (2012) · OncoImmunology · doi:10.4161/onci.21716 · Cited by 398

The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists

Thomas, S., Izard, J., Walsh, E. K., Batich, K. A., Chongsathidkiet, P., Clarke, G. A., Sela, D. A., Muller, A. J., Mullin, J. M., Albert, K., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2929 · Cited by 400

Photosensitizer Micelles Together with IDO Inhibitor Enhance Cancer Photothermal Therapy and Immunotherapy

Peng, J., Xiao, Y., Li, W., Yang, Q., Tan, L., Jia, Y., Qu, Y., & Qian, Z. (2018) · Advanced Science · doi:10.1002/advs.201700891 · Cited by 366

Metal Drugs and the Anticancer Immune Response

Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355

Amino acid metabolism in immune cells: essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy

Yang, L., Chu, Z., Liu, M., Zou, Q., Li, J., Liu, Q., Wang, Y., Wang, T., Xiang, J., & Wang, B. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01453-1 · Cited by 383

The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity

Mbongue, J., Nicholas, D., Torrez, T., Kim, N.-S., Firek, A., & Langridge, W. (2015) · Vaccines · doi:10.3390/vaccines3030703 · Cited by 351

Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors

Platten, M., Doeberitz, N. V. K., Oezen, I., Wick, W., & Ochs, K. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00673 · Cited by 348

Twelve immunotherapy drugs that could cure cancers

Cheever, M. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00604.x · Cited by 346

Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors

Ye, Y., Wang, J., Hu, Q., Hochu, G. M., Xin, H., Wang, C., & Gu, Z. (2016) · ACS Nano · doi:10.1021/acsnano.6b04989 · Cited by 342

Cytokines as a key component of cancer-related inflammation

Germano, G., Allavena, P., & Mantovani, A. (2008) · Cytokine · doi:10.1016/j.cyto.2008.07.014 · Cited by 334

Tumor promoting role of anti-tumor macrophages in tumor microenvironment

Goswami, K. K., Ghosh, T., Ghosh, S., Sarkar, M., Bose, A., & Baral, R. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.04.005 · Cited by 342

Trial watch: IDO inhibitors in cancer therapy

Vacchelli, E., Aranda, F., Eggermont, A. M. M., Sautès‐Fridman, C., Tartour, É., Kennedy, E. P., Platten, M., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.957994 · Cited by 333

Immune escape as a fundamental trait of cancer: focus on IDO

Prendergast, G. C. (2008) · Oncogene · doi:10.1038/onc.2008.35 · Cited by 331

Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy

Zhai, L., Spranger, S., Binder, D. C., Gritsina, G., Lauing, K. L., Giles, F. J., & Wainwright, D. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0420 · Cited by 327

Necroptosis in the Pathophysiology of Disease

Khoury, M. K., Gupta, K., Franco, S. R., & Liu, B. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2019.10.012 · Cited by 334

Characterization of the Kynurenine Pathway in Human Neurons

Guillemin, G. J., Cullen, K. M., Lim, C. K., Smythe, G. A., Garner, B., Kapoor, V., Takikawa, O., & Brew, B. J. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.4101-07.2007 · Cited by 331

Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR

Litzenburger, U. M., Opitz, C. A., Sahm, F., Rauschenbach, K. J., Trump, S., Winter, M., Ott, M., Ochs, K., Lutz, C., Liu, X., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1637 · Cited by 332

IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development

Smith, C., Chang, M. Y., Parker, K. H., Beury, D. W., DuHadaway, J. B., Flick, H. E., Boulden, J., Sutanto‐Ward, E., Soler, A. P., Laury‐Kleintop, L. D., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0014 · Cited by 326

Emerging targets in cancer immunotherapy

Burugu, S., Dancsok, A. R., & Nielsen, T. O. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.001 · Cited by 320

Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy

Grohmann, U., Volpi, C., Fallarino, F., Bozza, S., Bianchi, R., Vacca, C., Orabona, C., Belladonna, M. L., Ayroldi, E., Nocentini, G., et al. (2007) · Nature Medicine · doi:10.1038/nm1563 · Cited by 326

First-in-human phase I study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies

Beatty, G. L., O'Dwyer, P. J., Clark, J., Shi, J. G., Bowman, K. J., Scherle, P. A., Newton, R. C., Schaub, R., Maleski, J., Leopold, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2272 · Cited by 314

Control of immune response by amino acid metabolism

Grohmann, U., & Bronte, V. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00915.x · Cited by 321

A TDO2-AhR Signaling Axis Facilitates Anoikis Resistance and Metastasis in Triple-Negative Breast Cancer

D'Amato, N. C., Rogers, T. J., Gordon, M. A., Greene, L. I., Cochrane, D. R., Spoelstra, N. S., Nemkov, T. G., D'Alessandro, A., Hansen, K. C., & Richer, J. K. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-2011 · Cited by 294

Immunostimulant hydrogel for the inhibition of malignant glioma relapse post-resection

Zhang, J., Chen, C., Li, A., Jing, W., Sun, P., Huang, X., Liu, Y., Zhang, S., Du, W., Zhang, R., et al. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00843-7 · Cited by 307

Combinational strategy for high-performance cancer chemotherapy

Qin, S., Cheng, Y., Lei, Q., Zhang, A., & Zhang, X. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.027 · Cited by 304

Immune control by amino acid catabolism during tumorigenesis and therapy

Lemos, H. D. P., Huang, L., Prendergast, G. C., & Mellor, A. L. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0106-z · Cited by 282

Cnidarians as a Source of New Marine Bioactive Compounds—An Overview of the Last Decade and Future Steps for Bioprospecting

Rocha, J., Peixe, L. M. S. V., Gomes, N. C. M., & Calado, R. (2011) · Marine Drugs · doi:10.3390/md9101860 · Cited by 284

ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma

Scherpereel, A., Opitz, I., Berghmans, T., Psallidas, I., Glatzer, M., Comas, D. R., Astoul, P. J., Bölükbas, S., Boyd, J., Coolen, J., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00953-2019 · Cited by 273

Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells

Wu, A. A., Drake, V. E., Huang, H.-S., Chiu, S., & Zheng, L. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1016700 · Cited by 281

Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer

Prendergast, G. C., Malachowski, W. P., Mondal, A., Scherle, P., & Muller, A. J. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.07.004 · Cited by 277

The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy

Brochez, L., Chevolet, I., & Krüse, V. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.011 · Cited by 271

Necrostatin-1 and necroptosis inhibition: Pathophysiology and therapeutic implications

Cao, L., & Mu, W. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105297 · Cited by 272

Immune Suppression in the Tumor Microenvironment

Gajewski, T. F., Meng, Y., & Harlin, H. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000199193.29048.56 · Cited by 263

Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond

Muller, A. J., Manfredi, M. G., Zakharia, Y., & Prendergast, G. C. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0702-0 · Cited by 268

Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors

Muller, A. J., & Scherle, P. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1929 · Cited by 266

The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology

Curti, A., Trabanelli, S., Salvestrini, V., Baccarani, M., & Lemoli, R. M. (2008) · Blood · doi:10.1182/blood-2008-07-144485 · Cited by 268

Molecules in focus: Indoleamine 2,3-dioxygenase

King, N. J. C., & Thomas, S. R. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.01.004 · Cited by 265

The tumor‐draining lymph node as an immune‐privileged site

Munn, D. H., & Mellor, A. L. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00444.x · Cited by 254

Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer

Ino, K., Yoshida, N., Kajiyama, H., Shibata, K., Yamamoto, E., Kidokoro, K., Takahashi, N. K., Terauchi, M., Nawa, A., Nomura, S., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603477 · Cited by 249

Self‐Amplified Drug Delivery with Light‐Inducible Nanocargoes to Enhance Cancer Immunotherapy

Feng, B., Hou, B., Xu, Z., Saeed, M., Yu, H., & Li, Y. (2019) · Advanced Materials · doi:10.1002/adma.201902960 · Cited by 245

The immune system and inflammation in breast cancer

Jiang, X., & Shapiro, D. J. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.06.003 · Cited by 243

Indoleamine 2,3‐dioxygenase 1 (IDO1): an up‐to‐date overview of an eclectic immunoregulatory enzyme

Pallotta, M. T., Rossini, S., Suvieri, C., Coletti, A., Orabona, C., Macchiarulo, A., Volpi, C., & Grohmann, U. (2021) · FEBS Journal · doi:10.1111/febs.16086 · Cited by 255

Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase

Muller, A. J., Sharma, M. D., Chandler, P., DuHadaway, J. B., Everhart, M. E., Johnson, B. A., Kahler, D. J., Pihkala, J. P. S., Soler, A. P., Munn, D. H., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806173105 · Cited by 248

CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition

von Bergwelt‐Baildon, M. S., Popov, A., Šarić, T., Chemnitz, J. M., Claßen, S., Stoffel, M. S., Fiore, F., Roth, U., Beyer, M., Debey, S., et al. (2006) · Blood · doi:10.1182/blood-2005-08-3507 · Cited by 247

Inverse Correlation between Tumoral Indoleamine 2,3-Dioxygenase Expression and Tumor-Infiltrating Lymphocytes in Endometrial Cancer: Its Association with Disease Progression and Survival

Ino, K., Yamamoto, E., Shibata, K., Kajiyama, H., Yoshida, N., Terauchi, M., Nawa, A., Nagasaka, T., Takikawa, O., & Kikkawa, F. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4144 · Cited by 246

Role of indoleamine 2,3-dioxygenase in health and disease

Yeung, A. W. S., Terentis, A. C., King, N. J. C., & Thomas, S. R. (2015) · Clinical Science · doi:10.1042/cs20140392 · Cited by 244

Splicing Factor hnRNP A2/B1 Regulates Tumor Suppressor Gene Splicing and Is an Oncogenic Driver in Glioblastoma

Golan‐Gerstl, R., Cohen, M., Shilo, A., Suh, S., Bakàcs, A., Coppola, L., & Karni, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4410 · Cited by 233

Tryptophan-Degrading Enzymes in Tumoral Immune Resistance

van Baren, N., & den Eynde, B. J. V. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00034 · Cited by 237

In Brief

(2005) · Nature reviews. Cancer · doi:10.1038/nrc1578

101 Combinatorial cancer therapy using a pharmacological inhibitor of indoleamine 2,3-dioxygenase (IDO), a target of the cancer suppression gene Bin1

Muller, A. J., DuHadaway, J. B., Sutanto‐Ward, E., Donover, P. S., & Prendergast, G. C. (2004) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(04)80109-5

Breast Cancer Suppression by IDO Inhibition

Prendergast, G. C. (2005) · Defense Technical Information Center (DTIC)

Transcriptional control of IDO by the cancer suppression gene Bin1, a key mechanism for restraining tumor immune escape

Muller, A. J., DuHadaway, J. B., Sutanto‐Ward, E., Donover, P. S., & Prendergast, G. C. (2005) · Cancer Research · Cited by 1

Breast Cancer Suppression by IDO Inhibitors

Prendergast, G. C. (2006) · doi:10.21236/ada457476